Cannaccord Reiterates “Buy” Rating for Khiron Life Sciences

Khiron Launches Teleconsultation Services in Colombia

May 29, 2020 – Khiron Life Sciences (TSX-V: KHRN, OTC: KHRNF) receives a new price target from Canaccord Genuity. The analyst from Canaccord reiterated “Buy” rating for Khiron Life Sciences. The stock also received a price target of $2.80, suggesting that the stock has a possible upside of 364.96%. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

  • Rating: Buy
  • Price Target: $2.80
  • Institution: Canaccord Genuity

Source: MarketBeat

All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. Candlr is not receiving payment or commissions from companies for shared content on Candlr website unless its specified. View full disclaimer HERE.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.